Novel Bis(1,2,4-oxadiazolyl) Fused Thiazole Derivatives: Synthesis and Anticancer Activity

A novel series of bis-1,2,4-oxadiazole fused benzothiazole derivatives 9a-9j are synthesized, and their structures are confirmed by H-1 and C-13 NMR, and mass spectral data. All products are evaluated in vitro for their anticancer potential against a panel of four human cancer cell lines such as lung cancer (A549), breast carcinoma (MCF-7), melanoma (A375), and colon cancer (HT-29). The combretastatin-A4 is used as standard drug. All compounds 9a-9j exhibit significant anticancer activity with IC50 values ranging from 0.11 +/- 0.01 to 14.6 +/- 3.89 M. Among these, compounds 9a-9d, 9h, 9i demonstrate more potent activity than the control.